SLS
Companies
NASDAQ
Sellas Life Sciences Group Inc.
Health Care
$1.56
+$0.52 (+50.00%)
Price Chart
Overview
About SLS
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Market Cap
$83.7M
Volume
3.9M
Avg. Volume
3.2M
P/E Ratio
-3.7906976
Dividend Yield
0.00%
Employees
17.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.13
Moderate Correlation
Volatility
High (0.92)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, SLS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$83.7M
Volume3.9M
P/E Ratio-3.79
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 14, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025